Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
The clinical significance of genetic lesions within each lower-grade gliomas (LGG) subtype has not been fully elucidated. In this study, they identified sets of subtype-specific genetic and clinicopathological markers for each WHO subtype. The study subjects were a large cohort of patients who were genotyped for known or putative driver mutations and copy number variations associated with LGGs. Importantly, given that LGGs frequently have an indolent clinical history, the subjects were followed up for sufficiently long periods to accurately evaluate overall survival.
|